ACTION-1: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Oct 5, 2026 - P3 | N=343 | Active, not recruiting | Sponsor: RayzeBio, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Carcinoid Tumor • Endocrine Cancer • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR
|